---
layout: post
title: "Acromegaly: Developing Drugs for Treatment; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:35:27 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-01766
original_published: 2023-01-30 00:00:00 +0000
significance: 8.00
---

# Acromegaly: Developing Drugs for Treatment; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** January 30, 2023 00:00 UTC
**Document Number:** 2023-01766

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Acromegaly: Developing Drugs for Treatment." The purpose of this guidance is to provide recommendations to sponsors regarding clinical development of drugs for the treatment of patients with acromegaly. This draft guidance is intended to serve as a focus for continued discussions among the FDA Division of General Endocrinology, pharmaceutical sponsors, the academic community, and the public.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/01/30/2023-01766/acromegaly-developing-drugs-for-treatment-draft-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2023-01766

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
